Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment
2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
5 April 2022Portfolio NewsNitrase Therapeutics Receives New Grant from The Michael J. Fox Foundation for Parkinson’s Research
31 March 2022SV NewsKate Bingham interviewed by Beth Rigby, Sky News, on the lessons learnt from the UK Vaccine Taskforce
31 March 2022Portfolio NewsCerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism- 30 March 2022SV NewsKate Bingham shared the key lessons learnt from the success of the UK Vaccine Taskforce at The Royal Society’s recent Science of COVID-19 event.
25 March 2022Portfolio NewsPodimetrics Secures $45M for SmartMat to Prevent Diabetic Amputations in High-Risk Patients
24 March 2022Portfolio NewsImbria Pharmaceuticals Appoints John Young to its Board of Directors
20 March 2022SV NewsFast-track dementia to curb it like Covid
19 March 2022Portfolio NewsLoQus23: going upstream to slow Huntington’s disease- 18 March 2022Portfolio NewsNitrase Therapeutics Announces Major Discovery In Parkinson’s Disease Presented At The AD/PD International Conference
8 March 2022Portfolio NewsTRexBio Completes $26 Million Series A Extension Led by Polaris Partners to Advance Treatments for Immune-Mediated Diseases- 8 March 2022Portfolio NewsPionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY314
2 March 2022Portfolio NewsAlpheus Medical Announces Formation of World-Class Scientific Advisory Board (SAB) to Support Development of Novel Treatment for Brain Cancer
